Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 23, 2017

View Archived Issues

NIAID begins phase I study of mosquito-borne disease vaccine candidate

FDA issues complete response letter for Amphastar's intranasal naloxone

Affigen closes series A financing to support development of cancer immunotherapies

Truxima becomes the first biosimilar MAb in oncology to be granted E.U. marketing authorization

BIIB-076 enters phase I study for Alzheimer's disease

RON kinase, a potential new therapeutic target for cancer-induced bone destruction and osteoporosis

Aeolus Pharmaceuticals starts phase I study of new formulation of AEOL-10150

FDA approves Revlimid as maintenance therapy in multiple myeloma after autologous HSCT

Phase IIa data for GSK-2330672 in patients with primary biliary cholangitis with pruritus

Prometic Life Sciences reports results from phase II study of PBI-4050 in IPF

UB-421 monotherapy shows promise for HAART substitution

ImmusanT completes phase Ib study of Nexvax2

Kalytera Therapeutics reports phase IIa results for cannabidiol in GvHD

IMDC recommends discontinuation of ADAPT trial of rocapuldencel-T

Auris Medical extends collaboration with King's College London

Revive Therapeutics and InMed in term sheet agreement for cannabinoid therapies for kidney diseases

Phytecs and Yissum Research Development establish partnership

University of South Australia patents CDK4/cyclin D1 and/or CDK6/cyclin D3 inhibitors

FDA grants priority review to Zykadia sNDA for first-line treatment of ALK-positive NSCLC

NEOMED Institute discovers new bromodomain-containing protein 4 inhibitors

Achaogen announces milestone in development of plazomicin TDM assay

Sanofi launches Mozobil in Japan

NIH leads phase I study of DS-Cav1 vaccine for RSV

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 17, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for June 17, 2025.
Zusduri flurry ends; ‘set up’ at ODAC, Urogen prevails with FDA
BioWorld
During a conference call after the U.S. FDA approval of Zusduri (mitomycin), Urogen Pharma Ltd. CEO Liz Barrett offered candid observations about a...
23andme founder-led group outbids Regeneron for company
BioWorld
The 23andme Holding Co.’s saga came full circle with founder Anne Wojcicki regaining control of the bankrupt genetic testing company in a bidding battle against...
Elevidys’ second liver death hits Sarepta, sends DMD ripples
BioWorld
How the U.S. FDA might respond became a serious question for Wall Street as Sarepta Therapeutics Inc. made known a second death due to acute liver failure with...